Medicare Won’t Pay For Controversial Alzheimer’s Drug Aduhelm Without A New Trial In a key decision, the Centers for Medicare and Medicaid Services (CMS) said today that Medicare will not pay for the controversial Alzheimer’s drug Adulhelm until it sees positive results from a government-approved trial.